Current Evidence to Guide Practice, Policy, and Research: COVID-19 Vaccination During Pregnancy.
Summer Sherburne Hawkins
PMID 36736376WHAT IT FOUND
The reviewed evidence says COVID-19 vaccination in pregnancy is associated with no reported safety concerns, reduced severe maternal disease, and lower infant hospitalization.
Uptake remains low, especially among Black and Hispanic women.
Key findings
01Surveillance data comparing vaccinated and unvaccinated pregnant women found no safety concerns with the mRNA COVID-19 vaccine.
02One dose of CoronaVac was 67.7% effective and two doses were 85.4% effective against severe COVID-19 in pregnant women, with no deaths among partially or fully vaccinated women.
03Completing the two-dose mRNA primary vaccine series during pregnancy was associated with a 61% reduction in COVID-19-related hospitalizations among infants aged less than 6 months and an 80% reduction if the series was completed later in pregnancy.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This is a narrative review, not a systematic review, so it does not show how studies were selected or appraised. Pregnant women were excluded from the initial mRNA vaccine trials, so the safety and effectiveness evidence comes from surveillance, cohort, case-control, and data linkage studies. The review cites studies from different countries, vaccines, and variants, so the numbers may not apply to every patient. Vaccine uptake and misinformation data are from surveys and may not reflect current practice.
The easy way to misread this
Do not read this as a new randomized trial. Pregnant women were excluded from initial mRNA vaccine trials, and the safety and effectiveness figures come from observational comparisons.